Suzana Mustafa

Dr. Suzana Mustafa

Dr

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MZMOHD SHAFIE ZABIDI
MOHD SHAFIE ZABIDI
RBRUZILAWATI ABU BAKAR
RUZILAWATI ABU BAKAR
NMNurfadhlina Musa
Nurfadhlina Musa
SMSuzana Mustafa
Suzana Mustafa
WYWan Nazirah Wan Yusuf
Wan Nazirah Wan Yusuf
Understanding the pharmacokinetics parameter of colistin methanesulfonate sodium (CMS) and colistin is needed to optimize the dosage regimen in critically ill patients. However, there is a scarcity of pharmacokinetics parameters in this population. This review provides a comprehensive understanding of CMS and colistin pharmacokinetics parameters in this population. The relevant studies published in English that reported on the pharmacokinetics of CMS and colistin from 2000 until 2020 were systematically searched using the PubMed and Scopus electronic databases. Reference lists of articles were reviewed to identify additional studies. A total of 252 citation titles were identified, of which 101 potentially relevant abstracts were screened, and 25 full-text articles were selected for detailed analysis. Of those, 15 studies were included for the review. This review has demonstrated vast inter-study discrepancies in colistin plasma concentration and the pharmacokinetics parameter estimates. The discrepancies might be due to complex pathophysiological changes in the population studied, differences in CMS brand used, methodology, and study protocol. Application of loading dose of CMS and an additional dose of CMS after dialysis session was recommended by some studies. In view of inter-patient and intra-patient variability in colistin plasma concentration and pharmacokinetics parameters, personalized colistin dosing for this population is recommended.

30 March 2016 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SMSuzana Mustafa
Suzana Mustafa
WYWan Nazirah Wan Yusuf
Wan Nazirah Wan Yusuf
JWJean-Baptiste Woillard
Jean-Baptiste Woillard
TCTan Soo Choon
Tan Soo Choon
NHNorul Badriah Hassan
Norul Badriah Hassan

7 March 2022 in Gulhane Medical Journal
Verified
Journal Article
Closed access
SMSuzana Mustafa
Suzana Mustafa
SNSiti Latifah Azirah Mohd Noor
Siti Latifah Azirah Mohd Noor
RRRozitah Razman
Rozitah Razman
WYWan Nazirah Wan Yusuf
Wan Nazirah Wan Yusuf

1 January 2016 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
SMSuzana Mustafa
Suzana Mustafa
NHNorul Badriah Hassan
Norul Badriah Hassan
STSoo Choon Tan
Soo Choon Tan
MMMahiran Mustafa
Mahiran Mustafa
ARAhmad Kashfi AB Rahman
Ahmad Kashfi AB Rahman
WYWan Nazirah Wan Yusuf
Wan Nazirah Wan Yusuf
Background/aim: Nevirapine is a reverse-transcriptase inhibitor widely used in combination therapy to treat HIV infection. Nevirapine is extensively metabolized in the liver and CYP2B6 is mainly responsible for oxidation of 3-hydroxynevirapine (3-OH NVP). This study aims to explore CYP2B6 activity by measuring 2-hydroxynevirapine (2-OH NVP) and 3-OH NVP in plasma and to identify factors associated with nevirapine pharmacokinetic parameters. Materials and methods: A total of 112 patients were recruited and treated with nevirapine-based antiretroviral therapy. Plasma nevirapine and metabolite concentrations were assayed using high-performance liquid chromatography via liquid-liquid extraction. Results: Thirty-nine (34.8%) of the patients had no 3-OH NVP detected in their plasma while 2-OH NVP was detected in all patients. Metabolite concentrations were low compared to nevirapine. Positive correlations were observed between nevirapine and its metabolites, 2-OH NVP (P < 0.01) and 3-OH NVP (P = 0.012). Nevirapine concentration was decreased when concomitantly administered with methadone. Univariate analysis showed that ALT level, AST level, and detection of 3-OH NVP were associated with nevirapine pharmacokinetic parameters. Conclusion: The variability of nevirapine pharmacokinetic parameters was caused by liver enzymes and the presence of 3-OH NVP metabolites. The presence of 3-OH NVP can probably be used to distinguished CYP2B6 activity and efficacy of nevirapine in patients with HIV infection.